Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS™) to address fundamental challenges impacting systemic lupus erythematosus (SLE) studies and the integrity of the study endpoints.
eLAS is a therapeutic-specific application of Clinical Ink’s Lumenis™. Unlike other applications that simply offer stand-alone electronic versions of questionnaires, eLAS features a fully integrated suite of SLE disease assessment questionnaires, physical assessment, tender/swollen joint count, PGA, and summary forms.
Rather than having to reenter the same data on multiple disease assessments, eLAS allows the investigator to enter data once; the system auto-populates the appropriate fields across the required assessments, reducing time and eliminating errors. The system also ensures that adequate, relevant documentation is in place to support the investigator’s findings and disease assessment scale scoring, and it provides immediate access to the data for sponsor/CRO medical data review and adjudication teams for pre-randomization review and visit analysis.